R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Biotech’s biggest challenge isn’t scientific, but political ...

We speak to James Roosevelt Jr, a longtime healthcare leader, former associate commissioner of social security for retirement policy & grandson of FDR

R&D

How lab automation reinforces regulatory compliance for bioa...

Automation holds the potential to enhance scientific rigour and operational efficiency while solving long-standing regulatory conundrums.

R&D

Changing Faces – Boards of Directors and Advisory Boards – A...

Welcome back to Changing Faces, in our final round-up for August and September there are plenty of Board appointments to report on.

R&D

Reimagining biopharma: How AI is reshaping discovery, develo...

No longer confined to experimental pilots, AI is becoming a catalyst for change across the entire biopharma value chain - but there are challenges.

R&D

How a century-old technology could revolutionise LNP charact...

The utility of AUC in LNP characterisation is growing, thanks to ongoing efforts to improve the technology.

R&D

Staying on course: How hybrid FSP/FSO models are shaping cli...

Biotech and pharma companies increasingly require additional agility, flexibility, and operational efficiency in their clinical research operations.